secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002403
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron reports preliminary FY2021 U.S. EYLEA sales of $5.79B, REGEN-COV sales of $5.82B
--------------------------------------------------------------------------------

- EYLEA FY2021 U.S. net product sales ~$5.79B (+17% YoY); Q4 sales ~$1.54B (+15% YoY).
- REGEN-COV FY2021 U.S. net product sales ~$5.82B; Q4 sales ~$2.29B.
- Provided corporate update at J.P. Morgan conference; highlighted pipeline progress including Aflibercept 8mg Ph3 data expected 2H22.
- Dupixent annualizing at ~$6.6B run rate; three potential new Ph3 indications in 2022 (CSU, PN, EoE).
- Announced $3B share repurchase program in Nov 2021; over $7.5B repurchased since Nov 2019.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/0001104659-22-002403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465922002403/tm222431d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer